Quorum Review IRB Launches New Program for Phase I Healthy Clinical Trials
SEATTLE, WA (July 20, 2015): Quorum Review IRB, the premier central IRB, is introducing a comprehensive program that supports the unique needs of Phase I Healthy clinical trials. Quorum knows that Phase I units require immediate service and quick turnaround times. Quorum’s new program delivers.
With Quorum Review’s new Phase 1 Healthy Program, a study can be ready to enroll participants within a few days of submitting their materials. For changes mid-study, review and delivery of approval documents is even faster. Quorum’s new program also provides unprecedented alternatives in the review of recruitment materials. Quorum can conditionally approve recruitment materials before the protocol review is finalized, so you can more proactively plan for their deployment. If your group leverages generic recruitment templates and generic screening consent forms, Quorum’s new program makes using those materials easier than ever.
Quorum’s customers that have had the opportunity to preview the new Phase 1 Healthy Program proclaim it to be the “most intuitive service offering that exists for Phase 1 Healthy research.” “We know Phase I,” says Quorum’s CEO, Cami Gearhart. “We have Phase I researchers on our IRB panels and staff dedicated to supporting Phase I services. We are proud to offer our clients nimble turnaround times as well as the reliability of a large, accredited IRB.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.
